Dr Sud Agarwal, CEO of iNGENŪ CRO, an Australian CRO with specialist expertise in neuroscience, examines the recent resurgence in cannabinoid research and explains why Australia is at the epicentre.
Cannabinoid research is undergoing a significant global revival, and Australia has emerged as a central player, driven by a distinct combination of regulatory efficiency, financial incentives, and sophisticated scientific infrastructure.
Together, these elements have placed Australia at the front of the growing field of cannabinoid studies, drawing researchers and pharmaceutical companies from around the world.
The Australian advantage in cannabinoid research
Australia's prominence in cannabinoid research is built on several strategic strengths that ease the journey from early laboratory work through to clinical trials, supporting faster development and delivery of cannabinoid-based treatments.
1. Regulatory and economic environment
Australia's regulatory framework is well suited to cannabinoid research. The Therapeutic Goods Administration (TGA) offers an efficient approval pathway for clinical trials involving cannabinoids, covering import permissions, ethical approvals, and trial notifications in a timely manner. This efficiency cuts down on delays and allows faster movement from concept to clinical evaluation.
On the economic side, Australia provides strong incentives for research activity. The Research and Development Tax Incentive (RDTI) offers a 43.5% cash rebate on eligible research expenditures — direct financial support rather than a simple tax offset. This level of backing meaningfully improves the financial case for conducting high-quality research in Australia, attracting both local and international organisations.
2. Clinical research and patient recruitment
When it comes to clinical research, Australia has a well-established network of Contract Research Organisations (CROs) with deep expertise in cannabinoid therapies. Australian clinical sites and investigators tend to be receptive to patient recruitment for cannabinoid trials — an area that can be far more difficult in other countries due to cultural and regulatory obstacles.
The lack of a grey market for cannabis in Australia is another important factor. It means trial participants are unlikely to have used cannabis before enrolment, which protects the integrity of clinical results. This stands in contrast to places like the US and Canada, where cannabis is widely available and participant eligibility can become difficult to verify.
3. Societal and medical acceptance
More than seven years of legalised medical cannabis use has shaped a supportive, non-stigmatising environment for patients taking part in clinical trials. This cultural openness reduces the social barriers often tied to cannabis use, making it easier to recruit and retain participants across clinical studies.
4. Cost efficiency and operational performance
Research in Australia is also considerably more affordable than in the US, with costs running at roughly 70% less, owing to favourable currency exchange rates, the generous RDTI, and lower overall operating expenses. Clinical studies in Australia can also get underway in under eight weeks, which is substantially faster than in many comparable countries.
5. Patenting difficulties in the US
A major obstacle to cannabinoid research in the US is the country's conflicted legal position on cannabis. Although medical use is permitted in a number of states, cannabis remains illegal at the federal level, creating serious complications when seeking patents on cannabinoid-based discoveries. This also interferes with the ability to secure international patents for findings arising from US-based clinical trials.
The resulting legal uncertainty makes it hard for researchers and companies to safeguard their intellectual property globally, discouraging many potential sponsors from running trials in the US.
Australia as a leading destination for R&D
Australia's deliberate approach to promoting cannabinoid research has cemented its position as a global leader in the field. A favourable regulatory framework, substantial financial incentives, advanced clinical infrastructure, broad societal acceptance, and a clearer path to patent protection together make Australia a top choice for cutting-edge cannabinoid research and development.
- iNGENŪ CRO manages the majority of Australia's cannabinoid-related clinical trials. The country's favourable research environment has fostered a variety of collaborations and projects with iNGENŪ CRO currently performing more than nine clinical trials where the active pharmaceutical ingredient (API) is a cannabinoid.
Current cannabinoid clinical trials in Australia with iNGENŪ CRO include Australian companies like InhaleRx (ASX:IRX), Argent Biopharma (ASX:RGT) and Zelira Therapeutics (ASX:ZLD) and international companies like Oxford Cannabinoid Technologies (LSE:OCT) and some larger NASDAQ-listed entities in the US.
The cannabinoid studies being conducted in Australia are a mixture of phase I and II trials, mostly targeting major central nervous system disease including chronic epileptiform diseases, multiple sclerosis, orphan pain syndromes, Rett syndrome, narcolepsy and multiple different psychiatric disorders.
